P558: Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trialsECCO’23 CopenhagenYear: 2023
Authors: Regueiro, M.(1);Siegmund, B.(2)*;Yarur, A.(3);Steinwurz, F.(4);Gecse, K.B.(5);Goetsch, M.(6);Bhattacharjee, A.(7);Wu, J.(8);Green, J.(9);McDonnell, A.(10);Crosby, C.(11);Lazin, K.(12);Ferreira Branquinho, D.(13);Modesto, I.(14);Abreu, M.T.(15);
(1)Cleveland Clinic, Gastroenterology, Cleveland- Ohio, United States;(2)Medizinische Klinik für Gastroenterologie- Infektiologie und Rheumatologie- Charité - Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany;(3)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles- California, United States;(4)Hospital Israelita Albert Einstein, Gastroenterology, São Paulo, Brazil;(5)Amsterdam UMC, Gastroenterology, Amsterdam, The Netherlands;(6)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(7)Pfizer Healthcare India Pvt. Ltd., Biostatistics, Chennai, India;(8)Pfizer Inc, Biostatistics, Groton- Connecticut, United States;(9)Pfizer Inc, Field Medical- Gastroenterology, Collegeville- Pennsylvania, United States;(10)Pfizer Ltd, Safety Risk, Walton Oaks- Scurry, United Kingdom;(11)Pfizer Inc, Translational Medicine, New York- New York, United States;(12)Pfizer AG, Clinical Development, Zurich, Switzerland;(13)Pfizer Inc, Global Medical Affairs- Gastroenterology, Lisbon, Portugal;(14)Pfizer Inc, Global Medical Affairs- Gastroenterology, Madrid, Spain;(15)University of Miami Miller School of Medicine, Gastroenterology, Miami- Florida, United States;
P560: Curcumin-QingDai combination for patients with active ulcerative colitis: A randomized double-blinded placebo-controlled trialECCO’23 CopenhagenYear: 2023
Authors: Ben-Horin, S.(1);Salomon, N.(1)*;Karampekos, G.(2);Viazis, N.(2);Lahat, A.(1);Ungar, B.(1);Eliakim, R.(1);Kriger-Sharabi, O.(3);Reiss-Mintz, H.(4);Yanai, H.(5);Dotan, I.(6);Zittan, E.(7);Maharshak, N.(8);Hirsch, A.(9);Weitman, M.(10);Mantzaris, G.J.(2);Kopylov, U.(1);
(1)Sheba Medical Center- Tel-Avivi University, Gastroenterology, Ramat Gan, Israel;(2)Evangelismos-Polykliniki- GHA, Gastroenterology, Athens, Greece;(3)Assuta Medical Center, Gastroenterology, Ashdod, Israel;(4)Mayanei HaYeshua Medical Center, Gastroenterology, Bnei Brak, Israel;(5)Rabin Medical Center, Gastroenterology, - Petah Tikva, Israel;(6)Rabin Medical Center, Gastroenterology, Petah Tiqva, Israel;(7)Emek Medical Center, Gastroenterology, Afula, Israel;(8)Tel Aviv Medical Center, Gastroenterology, Tel-Aviv, Israel;(9)Tel-Aviv Medical Center, Gastroenterology, Tel-Aviv, Israel;(10)Bar-Ilan University, Chemistry, Ramat Gan, Israel;
P561: Risk of stoma formation in patients with Crohn's perianal fistulas over a two decades period. A cohort study from a tertiary referral center.ECCO’23 CopenhagenYear: 2023
Authors: Bislenghi, G.(1)*;Baldi, C.(1);Ferrante, M.(2);Sabino, J.(2);Verstockt, B.(2);Wolthuis, A.(1);Vermeire, S.(2);D'Hoore, A.(1);
(1)UZ Leuven, Abdominal Surgery, Leuven, Belgium;(2)UZ Leuven, Gastroenterology and Hepatology, Leuven, Belgium;
P562: Real world effectiveness and safety of ozanimod: One-year follow-up from a large tertiary centerECCO’23 CopenhagenYear: 2023
Authors: Cohen, N.A.(1)*;Choi, D.(1);Garcia, N.(1);Choi, N.(1);Picker, E.(1);Krugliak-Cleveland, N.(1);Cohen, R.(1);Dalal, S.(1);Sakuraba, A.(1);Pekow, J.(1);Rubin, D.(1);
(1)University of Chicago Medicine, IBD Center- Section of Gastroenterology- Hepatology and Nutrition, Chicago, United States;
P563: Monitoring of vedolizumab drug levels in a treat to target strategy for moderate-severe IBD (MOVE-IBD)ECCO’23 CopenhagenYear: 2023
Authors: Logan, H.(1)*;Rimmer, K.(1);Doecke, J.(2);Patrick, D.(1);
(1)Sunshine Coast University Public Hospital, Department of Gastroenterology and Hepatology, Sunshine Coast, Australia;(2)Royal Brisbane and Women's Hospital, CSIRO Health and Biosecurity/Australian E-Health Research Centre, Brisbane, Australia;
P564: vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn's disease – a meta-analysisECCO’23 CopenhagenYear: 2023
Authors: Yiu, T.H.(1)*;Leong, R.(2);Ko, Y.(2);Pudipeddi, A.(2);
(1)University of Sydney, Faculty of Medicine and Health, Sydney, Australia;(2)Concord Repatriation General Hospital, Gastroenterology and Liver Services, Sydney, Australia;
P565: Comparison of the efficacy of adalimumab and ustekinumab for prevention of intestinal fibrosis in bio-naive Crohn's Disease patientsECCO’23 CopenhagenYear: 2023
Authors: Biscanin, A.(1,2)*;Tomašić, V.(1);Babic, F.(1);Ćaćić, P.(1);Ogresta Kordej, D.(1);Hrabar, D.(1,2);Kralj, D.(1);Dorosulić, Z.(1);
(1)Sisters of Charity University Hospital, Department of Gastroenterology, Zagreb, Croatia;(2)University of Zagreb, School of medicine, Zagreb, Croatia;
P566: Colitis due to immunotherapy with anti-PD-1: a case seriesECCO’23 CopenhagenYear: 2023
Authors: De Ruvo, M.(1)*;Barberio, B.(1);Zingone, F.(1);Bonanno, L.(2);Dal Maso, A.(2);Stefano, F.(2);Chiarion Sileni, V.(3);Savarino, E.V.(1);
(1)University of Padua- Division of Gastroenterology, Department Of Surgery- Oncology And Gastroenterology, Padua, Italy;(2)Veneto Institute of Oncology IOV – IRCCS, Oncology 2 Unit- Department of Medical Oncology, Padua, Italy;(3)Veneto Institute of Oncology IOV – IRCCS, Melanoma Unit Department of Oncology, Padua, Italy;
P567: How can we predict the development of antibodies to infliximab in Crohn's disease?ECCO’23 CopenhagenYear: 2023
Authors: Ferreira, A.I.(1)*;Lima Capela, T.(1);Macedo Silva, V.(1);Xavier, S.(1);Arieira, C.(1);Cúrdia Gonçalves, T.(1);Dias de Castro, F.(1);Moreira, M.J.(1);Cotter, J.(1);
(1)Hospital da Senhora da Oliveira - Guimarães, Gastroenterology Department, Guimarães, Portugal;
P568: Patients with ulcerative colitis after pouch surgery are at risk for low spinal bone mineral density: a cross sectional studyECCO’23 CopenhagenYear: 2023
Authors: Pfeffer-Gik, T.(1)*;Godny , L.(1);Ollech, J.(1);Wasserberg, N.(2);White , I.(2);Barkan , R.(1);Cohen , S.(1);Avni-Biron, I.(1);Banai, H.(1);Snir, Y.(1);Yanai, H.(1);Yackobovich Gavan, M.(3,4);Shimon , I.(5);Tsvetov, G.(5);Broitman, Y.(1);Dotan, I.(1);
(1)Rabin Medical center- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Division of Gastroenterology, Petah Tikva, Israel;(2)Rabin Medical center- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Colorectal Unit- Division of Surgery, Petah Tikva, Israel;(3)Schneider Childrens Medical Center of Israel, The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes- National Center for Childhood Diabetes, Petah Tikva, Israel;(4)Tel Aviv University, Dept. of Epidemiology and Preventive Medicine- School of Public Health- Sackler Faculty of Medicine, Tel Aviv, Israel;(5)Rabin medical center- Beilinson campus- affiliated to the Sackler Faculty of Medicine- Tel Aviv University, Institute of endocrinology- diabetes and metabolism, Petah Tikva, Israel;
P570: Safety and Effectiveness of Tofacitinib in Ulcerative Colitis: Real-world Data from TOFA-UC, a SN-IBD StudyECCO’23 CopenhagenYear: 2023
Authors: Macaluso, F.S.(1)*;D'Antonio, E.(2);Fries, W.(3);Viola, A.(3);Ksissa, O.(3);Cappello, M.(4);Muscarella, S.(4);Belluardo, N.(5);Giangreco, E.(5);Mocciaro, F.(6);Di Mitri, R.(6);Ferracane, C.(7);Vitello, A.(8);Grova, M.(1);Renna, S.(1);Casà, A.(1);Ventimiglia, M.(9);Orlando, A.(1);
(1)“Villa Sofia-Cervello” Hospital, IBD Unit, Palermo, Italy;(2)Scuola Medica Salernitana- University of Salerno, Department of Medicine- Surgery and Dentistry, Salerno, Italy;(3)"G. Martino” Hospital, IBD Unit, Messina, Italy;(4)University of Palermo, Gastroenterology & Hepatology Section- PROMISE, Palermo, Italy;(5)“Guzzardi” Hospital, Gastroenterology Unit, Vittoria, Italy;(6)“ARNAS Civico - Di Cristina – Benfratelli” Hospital, Gastroenterology and Endoscopy Unit, Palermo, Italy;(7)“Vittorio Emanuele” Hospital, Gastroenterology Unit, Catania, Italy;(8)“S. Elia- Raimondi” Hospital, Gastroenterology and Endoscopy Unit, Caltanissetta, Italy;(9)Italian Ministry of Health, Directorate General of Medical Device and Pharmaceutical Service, Rome, Italy;Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
P571: Frequency and risk factors of advanced neoplasia in Korean IBD patients with Low Grade Dysplasia in previous surveillanceECCO’23 CopenhagenYear: 2023
Authors: Park, Y.E.(1)*;Kim, D.H.(2);Park, S.K.(3);Lee, Y.J.(4);Lee, C.K.(5);Kim, E.S.(6);Kim, K.O.(7);
(1)Inje University School of Medicine- Haeundae Paik Hospital, Division of Gastroenterology- Department of Internal Medicine, Busan, Korea- Republic Of;(2)Chonnam National University Hospital- Chonnam National University Medical School, Division of Gastroenterology- Department of Internal Medicine, Gwangju, Korea- Republic Of;(3)Kangbuk Samsung Hospital- Sungkyunkwan University School of Medicine, Division of Gastroenterology- Department of Internal Medicine and Gastrointestinal Cancer Center, Seoul, Korea- Republic Of;(4)Dongsan Medical Center- Keimyung University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Daegu, Korea- Republic Of;(5)Kyung Hee University-, Department of Internal Medicine- School of Medicine, Seoul, Korea- Republic Of;(6)Kyungpook National University, Division of Gastroenterology- Department of Internal Medicine- School of Medicine, Daegu, Korea- Republic Of;(7)Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Daegu, Korea- Republic Of;
P572: Coexisting Inflammatory bowel disease and Ankylosing spondylitis: Management and clinical outcomesECCO’23 CopenhagenYear: 2023
Authors: Savin, E.(1)*;Levartovsky, A.(2);Gendelman, O.(3);Lidar, M.(3);Ben-Horin, S.(2);Kopylov, U.(2);
(1)Sheba Medical Center, Department of Medicine 'B', Tel-Hashomer- Ramat Gan, Israel;(2)Sheba Medical Center, Department of Gastroenterology, Tel-Hashomer- Ramat Gan, Israel;(3)Sheba Medical Center, Rheumatology Unit, Tel-Hashomer- Ramat Gan, Israel;
P573: Change in fatigue in patients with Ulcerative Colitis or Crohn's disease initiating vedolizumab or other biologic therapy: Data from Belgian registry patientsECCO’23 CopenhagenYear: 2023
Authors: Louis, E.(1)*;Bossuyt, P.(2);Colard, A.(3);Caenepeel, P.(4);Baert, F.(5);Hantson, A.(6);Van Gassen, G.(6);Zhou, J.(7);Vermeire, S.(8);
(1)University Hospital CHU of Liège, Department of Gastroenterology, Liège, Belgium;(2)Imelda General Hospital, Imelda GI Clinical Research Center, Bonheiden, Belgium;(3)Hospital CHC, Department of Gastroenterology, Liège, Belgium;(4)Ziekenhuis Oost Limburg, Department of Gastroenterology, Genk, Belgium;(5)AZ Delta, Department of Gastroenterology, Roeselare, Belgium;(6)Takeda, Gastroenterology, Brussels, Belgium;(7)Takeda, Gastroenterology, Cambridge- MA, United States;(8)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;
P574: Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Siegmund, B.(1)*;Ryan, R.(2);Abreu, M.T.(3);Vermeire, S.(4);Dotan, I.(5,6);Goetsch, M.(7);Crosby, C.(8);Woolcott, J.(9);Komori, H.K.(10);Danese, S.(11);
(1)Charité - Universitätsmedizin Berlin, Medizinische Klinik für Gastroenterologie, Berlin, Germany;(2)Pfizer Inc, Biomarker Statistics, New York- New York, United States;(3)University of Miami Miller School of Medicine, Gastroenterology, Miami- Florida, United States;(4)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(5)Division of Gastroenterology- Rabin Medical Center, Gastroenterology, Petah Tikva, Israel;(6)Sackler Faculty of Medicine- Tel Aviv University, Gastroenterology, Tel Aviv, Israel;(7)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(8)Pfizer Inc, Translational Medicine, New York- New York, United States;(9)Pfizer Inc, Global Medical Affairs- Gastroenterology, Collegeville- Pennsylvania, United States;(10)Kinevant Sciences, Translational Research, San Diego- California, United States;(11)Gastroenterology and Endoscopy- IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;
P575: Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 CopenhagenYear: 2023
Authors: Siegmund, B.(1)*;Komori, H.K.(2);Abreu, M.T.(3);Vermeire, S.(4);Dotan, I.(5,6);Goetsch, M.(7);Crosby, C.(8);Ryan, R.(9);Woolcott, J.(10);Danese, S.(11);
(1)Medizinische Klinik für Gastroenterologie- Infektiologie und Rheumatologie- Charité - Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany;(2)Kinevant Sciences, Translational Research, San Diego- California, United States;(3)University of Miami Miller School of Medicine, Gastroenterology, Miami- Florida, United States;(4)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;(5)Division of Gastroenterology- Rabin Medical Center, Gastroenterology, Petah Tikva, Israel;(6)Sackler Faculty of Medicine- Tel Aviv University, Gastroenterology, Tel Aviv, Israel;(7)Pfizer AG, Global Clinical Development, Zurich, Switzerland;(8)Pfizer Inc, Translational Medicine, New York- New York, United States;(9)Pfizer Inc, Biomarker Statistics, New York- New York, United States;(10)Pfizer Inc, Global Medical Affairs- Gastroenterology, Collegeville- Pennsylvania, United States;(11)Gastroenterology and Endoscopy- IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;
P576: Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CDECCO’23 CopenhagenYear: 2023
Authors: D'Haens, G.(1)*;Bossuyt, P.(2);Baert, F.(3);Molnár, T.(4);Clasquin, E.(1);Lowenberg, M.(1);Montazeri, N.(1);Peeters, H.(5);Lambrecht, G.(6);Vermeire, S.(7);
(1)Amsterdam University Medical Centres, Gastroenterology, Amsterdam, The Netherlands;(2)Imelda General Hospital, Gastroenterology, Bonheiden, Belgium;(3)AZ Delta, Gastroenterology, Roeselare, Belgium;(4)University of Szeged, Internal Medicine, Szeged, Hungary;(5)St Lukas Hospital, Gastroenterology, Gent, Belgium;(6)MSD, Gastroenterology, Oostende, Belgium;(7)University Hospital Leuven, Gastroenterology, Leuven, Belgium;
P577: A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Peyrin-Biroulet, L.(1)*;Danese, S.(2);Colombel, J.F.(3);Rieder, F.(4);Yarur, A.(5);Verstockt, B.(6);Lichtiger, S.(7);Mosig, R.(8);Cataldi, F.(7);Feagan, B.(9);
(1)Nancy University Hospital- University of Lorraine, Department of Gastroenterology and Inserm NGERE U1256, Vandoeuvre-lès-Nancy, France;(2)IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Department of Gastroenterology and Digestive Endoscopy, Milan, Italy;(3)Icahn School of Medicine at Mount Sinai, The Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(4)Cleveland Clinic, Department of Inflammation and Immunity- Lerner Research Institute- Department of Gastroenterology- Hepatology and Nutrition- Digestive Disease Institute, Cleveland, United States;(5)Cedars Sinai Medical Center, Division of Gastroenterology and Hepatology- Center for Inflammatory Bowel Diseases, Los Angeles, United States;(6)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology- Department of Chronic Diseases and Metabolism, Leuven, Belgium;(7)Landos Biopharma- Inc, Clinical, Blacksburg, United States;(8)Landos Biopharma- Inc, Corporate Development, Blacksburg, United States;(9)Western University, Division of Gastroenterology- Department of Medicine, London, Canada;
